| Literature DB >> 24053215 |
W A Nuwan Kumara1, Thisara Perera, Mekhala Dissanayake, Priyanga Ranasinghe, Godwin R Constantine.
Abstract
BACKGROUND: To study the prevalence and define deferential risk factors for 'Resistant' hypertension (RHT) in a hypertensive population of South Asian origin.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24053215 PMCID: PMC3848873 DOI: 10.1186/1756-0500-6-373
Source DB: PubMed Journal: BMC Res Notes ISSN: 1756-0500
Co-morbidities in all adults, in those with and without resistant hypertension
| | | |||
|---|---|---|---|---|
| DM | 118 (42.6%) | 37 (69.9%) | 81 (36.1%) | < 0.001 |
| IHD | 214 (77.3%) | 48 (90.6%) | 161 (71.9%) | < 0.01 |
| Hyperlipideamia | 144 (52%) | 26 (49.1%) | 118 (52.7%) | NS |
| CKD | 9 (3.2%) | 3 (5.7%) | 6 (2.7%) | NS |
CKD Chronic Kidney Disease, DM Diabetes Mellitus, IHD Ischaemic Heart Disease, NS Not Significant; *, p values for ‘Resistant’ Vs. ‘Non-resistant’ groups.
Usage of drugs in those with and without resistant hypertension
| | | |||
|---|---|---|---|---|
| Anti-hypertensives | | | | |
| ACEI | 151 (54.5%) | 37 (69.8%) | 114 (50.9%) | <0.05 |
| α-blockers | 21 (7.6%) | 14 (26.4%) | 7 (3.1%) | <0.001 |
| ARB | 94 (33.9%) | 22 (41.5%) | 72 (32.1%) | NS |
| β-blockers | 143 (51.6%) | 38 (71.7%) | 105 (46.9%) | <0.01 |
| CCBs | 131 (47.3%) | 29 (54.7%) | 102 (45.5%) | NS |
| Furosemide | 59 (21.3%) | 26 (49.1%) | 33 (14.7%) | <0.001 |
| Spiranolactone | 8 (2.9%) | 6 (11.3%) | 2 (0.9%) | <0.01 |
| Thiazide | 34 (12.3%) | 16 (30.2%) | 18 (8.0%) | <0.001 |
| Other drugs | | | | |
| Anti platelets | 201 (72.6%) | 37 (69.8%) | 174 (77.7%) | NS |
| Lipid lowering drugs | 152 (54.9%) | 25 (47.1%) | 127 (56.7%) | NS |
| Nitrates | 139 (50.2%) | 26 (49.1%) | 113 (50.4%) | NS |
ACEI Antgiotensin Converting Enzyme Inhibitors, ARB Angiotensin-II Receptor Blockers, CCB Calcium Channel Blockers, NS Not Significant; *, p values for ‘Resistant’ Vs. ‘Non-resistant’ groups.
Cardiovascular risk factors in those with and without resistant hypertension
| | | |||
|---|---|---|---|---|
| Non modifiable | | | | |
| Age (> 55 years) | 202 (72.9%) | 46 (86.8%) | 156 (69.6%) | < 0.05 |
| Gender – Male | 139 (50.2%) | 28 (52.8%) | 111 (49.5%) | NS |
| Gender – Female | 138 (49.8%) | 25 (47.2%) | 113 (50.4%) | NS |
| Family history | 126 (45.5%) | 29 (54.7%) | 97 (43.3%) | NS |
| Modifiable | | | | |
| High salt intake | 61 (22.0%) | 12 (22.6%) | 49 (21.9%) | NS |
| Tobacco smoking | 16 (5.8%) | 1 (1.9%) | 15 (6.7%) | NS |
| Hyperlipidaemia | 142 (51.3%) | 24 (45.3%) | 118 (52.7%) | NS |
| Diabetes mellitus | 111 (40.1%) | 30 (56.6%) | 81 (36.2%) | < 0.01 |
| Obesity (BMI > 27.5 kg/m2) | 185 (66.8%) | 42 (79.2%) | 143 (63.8%) | < 0.05 |
| Alcohol consumption | 29 (10.5%) | 7 (13.2%) | 22 (9.8%) | NS |
BMI Body Mass Index, NS Not Significant; *, p values for ‘Resistant’ Vs. ‘Non-resistant’ groups.
Binary logistic regression analysis of factors associated with resistant hypertension
| Age | 1.36 (1.14 – 1.56) | <0.05 |
| Gender – female | Reference | |
| male | 1.52 (0.67 – 3.47) | NS |
| Duration of hypertension | 1.76 (1.26 – 2.28) | <0.05 |
| Current smoking - non-smoker | Reference | |
| smoker | 1.51 (0.25 – 9.01) | NS |
| Alcohol consumption - no | Reference | |
| yes | 2.81 (0.96 – 8.20) | NS |
| Diabetes Mellitus – absent | Reference | |
| present | 1.67 (1.31 – 1.97) | <0.05 |
| IHD – absent | Reference | |
| present | 0.59 (0.12 – 2.50) | NS |
| CKD - absent | Reference | |
| present | 0.79 (0.39 – 1.58) | NS |
| Hyperlipidaemia - absent | Reference | |
| present | 1.16 (0.54 – 2.48) | NS |
| Obesity - BMI <27.5 | Reference | |
| BMI > =27.5 | 1.84 (1.04 – 3.26) | <0.05 |
| High salt intake – absent | Reference | |
| present | 1.96 (0.94 – 2.95) | NS |
BMI Body Mass Index, CKD Choric Kidney Disease, IHD Ischaemic Heart Disease.